Even Very Low Dose Rivaroxaban Prevents Recurrent VTE

ACC Conference Reporter

ACC.17 | WASHINGTON, DC — Continuing use of rivaroxaban (Xarelto) at either 20 mg or 10 mg dose appears to reduce the risk of recurrent venous thromboembolism without increasing the risk for bleeding. Read More >>>

Keywords: ACC17, ACC Annual Scientific Session

< Back to Listings